First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.

被引：1
|
作者：
Beslija, S. [1 ]
Brodowicz, T. [1 ]
Greil, R. [1 ]
Inbar, M. J. [1 ]
Kahan, Z. [1 ]
Kaufman, B. [1 ]
Lang, I. [1 ]
Steger, G. G. [1 ]
Stemmer, S. M. [1 ]
Zielinski, C. [1 ]
Zvirbule, Z. [1 ]
机构：
[1] CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/000B-5472.SABCS11-OT2-01-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-02
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data
    Inbar, M.
    Lang, I.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G. G.
    Zielinski, C. C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S346 - S346
  • [2] SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)
    Lang, I.
    Inbar, M.
    Greil, R.
    Kahan, Z.
    Beslija, S.
    Steger, G. G.
    Stemmer, S. M.
    Zvribule, Z.
    Kaufman, B.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
  • [3] Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
    Lam, Siu W.
    Nota, Nienke M.
    de Groot, Steffen M.
    Jager, Agnes
    Bos, Monique M. E. M.
    Linn, Sabine C.
    van den Bosch, Joan
    Braun, Hans J.
    van der Velden, Ankie M. T.
    Los, Maartje
    Portielje, Johanneke E. A.
    Kroep, Judith R.
    Honkoop, Aafke H.
    Smorenburg, Carolien H.
    Tanis, Bea
    van Riel, Johanna M. G. H.
    Terwogt, Jetske M. Meerum
    den Boer, Marien O.
    Douma, Joep
    Jeurissen, Frank
    Berends, Johan
    van Tinteren, Harm
    Boven, Epie
    CANCER RESEARCH, 2015, 75
  • [4] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
    Lang, I.
    Inbar, M.
    Steger, G.
    Greil, R.
    Zvirbule, Z.
    Beslija, S.
    Kahan, Z.
    Taskova, V.
    Kaufmann, B.
    Zielinski, C. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 278
  • [5] Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG).
    Lam, S. W.
    de Groot, S. M.
    Honkoop, A. H.
    Jager, A.
    ten Trje, A. J.
    Bos, M. M. E. M.
    Linn, S. C.
    van den, Bosch J.
    Nortier, J. W. R.
    Braun, J. J.
    de Graaf, H.
    Portielje, J. E. A.
    Los, M.
    Gooyer, D. D.
    van Tinteren, H.
    Boven, E.
    CANCER RESEARCH, 2011, 71
  • [6] Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
    Lam, S. W.
    de Groot, S. M.
    Honkoop, A. H.
    Jager, A.
    ten Tije, A. J.
    Bos, M. M. E. M.
    Linn, S. C.
    van den Bosch, J.
    Kroep, J. R.
    Braun, J. J.
    van Tinteren, H.
    Boven, E.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3077 - 3088
  • [7] Bevacizumab A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Croom, Katherine F.
    Dhillon, Sohita
    DRUGS, 2011, 71 (16) : 2213 - 2229
  • [8] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.
    Lang, I.
    Inbar, M. J.
    Greil, R.
    Steger, G. G.
    Beslija, S.
    Kahan, Z.
    Eniu, A. E.
    Zvirbule, Z.
    Sirbu, D. E.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Brodowicz, T.
    Pienkowski, T.
    Beslija, S.
    Melichar, B.
    Lang, I.
    Inbar, M. J.
    Anghel, R.
    Spanik, S.
    Ahlers, S.
    Zielinski, C.
    CANCER RESEARCH, 2013, 73
  • [10] Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
    Lang, I.
    Inbar, M. J.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G. G.
    Messinger, D.
    Brodowicz, T.
    Zielinski, C.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (17) : 3140 - 3149
12345